These data support a mechanism of HER3/HER2 activation and migration by ASPN in prostate cancer, thereby highlighting HER2 and HER3 as potential therapeutic vulnerabilities in metastatic prostate cancer. This evidence concerns the gene ERBB2 and Familial prostate cancer.